Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact?

By Christopoulos Panagiotis   Mastorakos George   Gazouli Maria   Deligeoroglou Efthymios   Katsikis Ilias   Diamanti-Kandarakis Evanthia   Panidis Dimitrios   Creatsas George  

Gynecological Endocrinology, Vol. 26, Iss. 9, 2010-09 ,pp. : 698-703

Informa Healthcare

Access to resources Recommend Favorite

The role of genes in the polycystic ovary syndrome: Predisposition and mechanisms

By Deligeoroglou Eythimios   Kouskouti Christina   Christopoulos Panagiotis  

Gynecological Endocrinology, Vol. 25, Iss. 9, 2009-09 ,pp. : 603-609

Informa Healthcare

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome

By  

Current Vascular Pharmacology, Vol. 15, Iss. 3, 2017-04 ,pp. : 218-229

Bentham Science Publishers

Access to resources Recommend Favorite

Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered

By Nur Torun Ayse   Vural Mehmet   Cece Hasan   Camuzcuoglu Hakan   Toy Harun   Aksoy Nurten  

Gynecological Endocrinology, Vol. 27, Iss. 12, 2011-12 ,pp. : 988-992

Informa Healthcare

Access to resources Recommend Favorite

The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome

By Ertunc D.  

Human Reproduction, Vol. 20, Iss. 5, 2005-05 ,pp. : 1207-1212

Oxford University Press

Access to resources Recommend Favorite